The ,B-adrenergic blocker, practolol, proved to be an effective antihypertensive agent in a single-blind crossover trial, involving I7 patients with essential hypertension of mild to moderate severity. After a 2-month placebo period, dosage was begun at IOO mg twice a day, and titrated against blood pressure response up to a maximum dose of 400 mg twice a day, leading to an average reduction in blood pressure of 20/18 mmHg, and satisfactory control in I4 of I6 patients (one defaulter). The clinical and physiological data were analysedfor prediction of response to practolol. The urinary noradrenaline response to head-up tilt, an index of the responsiveness of the sympathetic nervous system, correlated significantly with subsequent blood pressure reduction with practolol IOO mg twice a day (r=0-62, P< O.OI). In 8 patients, responsiveness to tilt was retested after control of blood pressure: changes in diastolic blood pressure and pulse rate while on practolol were both significantly less than pretreatment responses. The urinary noradrenaline response was also reduced (+o -o 5,tg/hr vs. pretreatment mean of + i *64,tg/hr; P< o oI), a finding not explicable in terms of known receptor-blocking properties of the drug. It is suggested that the antihypertensive action of /3-adrenergic blockers may be related to a reduction in the reflex activity of the sympathetic nervous system. Plasma renin activity, which was normal in the recumbent state, rose with tilting. The response with tilt was significantly reduced with practolol, though plasma renin activity during recumbency was only marginally lowered by the drug.
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Although fl-adrenergic blocking drugs are finding increasing application in the treatment of hypertension, the mechanism by which they lower blood pressure remains uncertain. The antihypertensive effect has been attributed to a reduction in cardiac output (Frohlich et al., I968 ) but a satisfactory reduction in blood pressure with oral medication has been stated to occur after a latent period of several weeks (Prichard and Gillam, I969) , whereas the effect on cardiac output is rapid. An unexplained phenomenon is the extreme range of sensitivity to the blood pressure-lowering effects of ,B-blockers shown by essential hypertensives, dose requirements of propranolol varying between perhaps o-i and 3 g daily (Zacharias, I97I; Prichard, 1970) .
Essential hypertensives exhibit a broad range of sympathetic nervous system responsiveness when subjected to postural stresses, extending from underactivity in patients responding to tilting with pos-tural hypotension, through to increased activity in so-called 'orthostatic hypertensives' who display greater than normal rises in blood pressure and noradrenaline (Frohlich et al., I967; Esler, I970) . On the basis of our earlier studies (Esler, I970) , we have investigated the relation between sympathetic responsiveness to change in posture and subsequent sensitivity to the blood pressure-lowering effect of a f-adrenergic blocker.
Oral administration of propranolol produces a fall in blood pressure which is associated with a reduction in cardiac output, but total peripheral vascular resistance is increased (Frohlich et 
Laboratory investigations
Changes in blood pressure with tilting, urinary noradrenaline (corrected for changes in glomerular filtration rate), and plasma renin activity were measured. The experimental procedure was as follows: after an overnight fast, subjects were rested supine in a single-bed ward for go minutes before the beginning of the study, at the end of which they emptied their bladder. Smoking was forbidden, and drinking water was given throughout to ensure an adequate urine flow. Then after go minutes of recumbent rest, a timed urine sample was collected for assay of catecholamines and creatinine. Blood was drawn at this stage, after 3 hours of recumbency, for assay of serum creatinine and plasma renin activity.
When blood pressure had stabilized after the venepuncture, the patients were tilted head-up at 250 on a tilttable for a further go minutes. Blood pressure was measured at frequent intervals with a sphygmomanometer, with the cuff at heart level. At the end of this period of tilt, further samples of blood and urine were collected for assay of catecholamines, creatinine, and plasma renin activity.
Urinary free noradrenaline and adrenaline were determined in duplicate using the method of Crout (I96I), by differential fluorimetry using 2 sets of filters (von Euler and Lishajko, I959).
Urinary creatine was measured by a modification of the alkaline picrate method (Edwards and Whyte, 1958) , serum creatinine by autoanalyser. Plasma renin activity was determined by the bioassay method of Skinner (I967) using the anaesthetized ganglion-blocked rat. The difference between 24 duplicate measurements of plasma renin activity was 6 ± 9 per cent (mean + standard deviation). The assay was performed in duplicate on 2 different rats, and was repeated if duplicates differed by more than 24 per cent (mean difference +2 SD).
Drug trial design
The antihypertensive effect of practolol was evaluated in a single-blind crossover trial in which a placebo was given for 2 months followed by a fixed dose of practolol, I00 mg twice daily, for 6 months. The dose was then titrated against blood pressure response up to a maximum dose of 400 mg twice a day. The pretreatment blood pressure value was the mean of 4 readings obtained from two-weekly outpatient attendances over the 2 months on placebo. There was no fall in blood pressure during this time. The treatment blood pressure on the ioo mg twice daily dose schedule was the mean of all outpatient readings taken at intervals of 2 to 3 weeks over the past 4 months of the 6-month period on practolol. If the recumbent blood pressure exceeded 150/90 numHg after 6 months, the dose was increased until blood pressure was reduced to this level, or until an arbitrary maximum dose of 400 mg twice a day was being given. Lying blood pressures were measured, by a single observer with a sphygmomanometer bag, dimensions 30 x I225 cm, after 3 to 5 minutes of recumbent rest. Standing blood pressures were measured after the patient had been standing for I to 2 minutes.
Results
The effect of practolol Ioo mg twice daily on pulse rate and supine and standing blood pressures is shown in the each observed once, but did not require treatment to be stopped.
The rate of fall of blood pressure on a constant dose of I00 mg practolol twice daily is shown in Fig. i . In the 7 patients who were controlled on this dose, the maximum fall in blood pressure had virtually been attained by the time of the first outpatient attendance after 2 weeks of treatment (Fig.  i ). There were no delayed falls in these patients, or in the others with smaller initial responses to this dose. On restarting the placebo, the return of the blood pressure to pretreatment levels was slow, being of the order of 4 to 6 weeks ( Fig. i, Some essential hypertensives are very sensitive to the blood pressure-lowering effects of ,B-adrenergic blockers. We tried to classify these retrospectively on clinical and physiological grounds. Some indices did not predict sensitivity to practolol. Blood pressure reduction on the low dose was unrelated to the initial level of the blood pressure (within the narrow range encompassed in this study), severity index, resting pulse rate, plasma renin activity, or the supplemental blood pressure (Smirk, I944) (casual blood pressure minus basal blood pressure, a measure of the lability of the hypertension). correlation between the urinary noradrenaline response to tilt and subsequent blood pressure reduction (r = 0-62, P < O-OI; Fig. 2 ). The correlation between diastolic blood pressure response to tilt and subsequent blood pressure reduction on practolol was of a lower order (r=0-42, 0-I >P>o -05) but orthostatic hypertensives, with a diastolic blood pressure rise of > I0 mmHg (Esler, I970) , as a group had a larger fall in mean blood pressure than the hypertensives with normal or reduced blood pressure responses to tilt (fall in mean blood pressure 23-I±II-7 mmHg vs. i0-8±9-7, P<o-o5).
In 8 patients, in whom the blood pressure had been satisfactorily controlled with either 200 mg (7) or 400 mg (i) daily, the responses to tilting were retested after an interval of 9 to 24 months. The blood pressure, pulse rate, and urinary noradrenaline responses were all significantly diminished (Fig. 3) . Five of these patients were restarted on placebo, and after an interval of 2 to 3 months during which blood pressures rose to near pretreatment levels, responses were measured a third time. Tilt responses on placebo, including the noradrenaline response, were greater than on practolol, and had returned towards pretreatment figures (Fig. 3) .
In 8 patients the effect of practolol on plasma renin activity was measured. Plasma renin activity was measured after 3 tO 4 hours of recumbent rest, and after go minutes of 25' head-up tilt, once before treatment, and again on practolol. There was no restriction of dietary sodium intake in these patients. Though big falls in unstimulated plasma renin activity occurred with practolol in the 3 patients in whom it was initially high, the difference overall was not significant at the 5 per cent level; I-9I ± 0-46 ng/ml/hr (mean ± standard deviation) vs. I-25 ± 0-34 on practolol; o os < P < o-I paired t test. The plasma renin activity response to tilt was significantly diminished on practolol ( Fig. 4 ; P < o-oi).
Discussion
The antihypertensive effect of oral propranolol therapy is associated with a fall in cardiac output, but total peripheral vascular resistance is raised (Frohlich et al., I968) . Because practolol has much less activity on ,B-adrenergic peripheral vasodilator receptors in skeletal muscle than propranolol (Barrett, I97I) and chronic oral administration of practolol is not associated with increase in total vascular resistance (Bodem et al., I971) , it was anticipated that practolol too would lower blood pressure in essential hypertension, and perhaps be more potent in this regard than propranolol. In this trial, practolol proved to be an effective antihypertensive agent in patients with moderate sustained essential hyper- tension. A similar finding has been repori other groups of workers (Prichard, Boakes I97I; Waal-Manning, I970). The antihy activity relative to that of propranolol re certain. In the only comparative trial (V ning, I970), propranolol and practolol v to be of similar potency, but since a 2-wee} design had been used, a residual effect pressure from the previous fl-adrenerg may still have been present when the se was being evaluated.
As has been found previously with p (Zacharias, 197I; Prichard, I970) The mechanism by which practolol produced this reduction in reflex sympathetic activity is unknown. An increase in blood volume can reduce orthostatic responsiveness (Jeffrey, Fareeduddin, and Abelmann, I970) . Blood volume was not altered by practolol in 3 patients in whom it was measured, and in fact, reduction in plasma volume with propranolol has recently been reported (Tarazi, Frohlich, and Dustan, I97I) . Though there is some indirect evidence of a reduction in baroreceptor sensitivity by propranolol in dogs (Booker et al., I969) , observations in man do not support this finding Practolol (Sleight, Gribbin, and Pickering, I97i ). An effect 0P1r7±C0o on central noradrenergic neurones is a possible explanation since the occasional side-effect of increase in troublesome dreams (Wiseman, I97I) suggests that 'asma renin practolol enters the central nervous system. What )n practolol relation, if any, this reduction in reflex sympathetic nervous system activity has to the antihypertensive action of the drug is uncertain, but it has often been ted by two suggested that repeated, greater than normal, reflex , and Day, responses to pressor stimuli occurring in borderline Tpertensive hypertension may contribute to the genesis of susmains un-tained hypertension. 'aal-Man-
The search for the best existing drug for a parvere found ticular patient with essential hypertension is largely k crossover a matter of trial and error. With fl-blockers, the on blood main therapeutic guideline relates to the exclusion ,ic blocker of certain patients, such as those with uncontrolled cond drug heart failure or a history of bronchospasm, there being no clear-cut grounds for preferring this class )ropranolol of drugs to another. Subgroups of patients with tial hyper-essential hypertension may exist who would be ex-E of sensi-pected to be highly sensitive to ,B-adrenergic lough pre-blockers, such as those with 'hyperdynamic fSensitivity adrenergic disease' (Frohlich, Tarazi, and Dustan, actolol was I969) in whom a raised blood pressure is associated pulse rate, with cardiac symptoms, such as palpitations, and measure of excessive sensitivity to infused fl-agonist can be he sympa-demonstrated. The orthostatic hyperresponders Elated with described in this study may prove to be another le haemo-group in whom a fl-blocker might be a logical first change in line drug, though it is clear that with adequate thetic ner-dosage, satisfactory control can be achieved in the e response majority of hypertensive patients (Zacharias, I97I; I970 
